Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411696 · ClinicalTrials.gov registry record
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 289
- Enrollment target
NCT01411696 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 289 participants.
The verdict
NCT01411696 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 289 participants
- Enrollment target
Study Summary
This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits. All data was collected via chart review.
Interventions
- DRUG dexamethasone intravitreal implant 0.7 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411696
The ClinicalTrials.gov registry entry for NCT01411696 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dexamethasone intravitreal implant 0.7 mg is the first listed.
NCT01411696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411696 about?
NCT01411696 is a clinical study titled "Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)". This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits. All data was collected via chart review.
What is the current status of trial NCT01411696?
This trial is currently completed. The enrollment target is 289 participants. The study started on 2011-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01411696?
The interventions under investigation include: dexamethasone intravitreal implant 0.7 mg (DRUG).
Who is sponsoring clinical trial NCT01411696?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.